About Bion
Bionpharma operates as a pharmaceutical company specializing in the development of generic pharmaceutical products. We manufacture, market, and distribute over 50 drugs in the US and international markets. Additionally, we partner with other pharmaceutical companies for the in-licensing and out-licensing of generic and over-the-counter products.
About us
Fast Growing
Pharma Company
Bionpharma specializes in developing and commercializing high-quality generic medications for both prescription and over-the-counter products. We are also one of the largest suppliers of soft gel capsules in the US, and we offer certain OTC products through an online presence on Amazon.
Products
0
+
Patents
0
Employees Worldwide
0
Cities
0
Our Services
See More About
Us Here
We are a fully scale manufacturing and distribution pharmaceutical company with R&D capabilities.
Our Milestones
2023
- Acquisition of a liquid portfolio
- Capability enhancement at Orbion for liquid manufacturing, sachets and PFOS formulations
- Development of products for niche hospital segment of the market
- Growth and launch of new private label products. Foray into niche monograph segmen
2022
- Invested in an OTC company/ products in Texas, USA
- Launching multiple products from OrBion
- Filing multiple products from OrBion
2021
- Divestment of CoreRx. USA for substantial gain distributed Dividend
- Acquisition of OrBion Chennai, India to provide Bion with a manufacturing facility and 28 ANDAS
- Launched Bion's first FTF product
- First product developed in-house filed with the FDA
2020
- Acquisition of development facility in Bangalore, India to internalize the development of new products
- Established e-commerce platform on Amazon for OTC products
- Expanded retail presence for OTC products
2019
- Expanded the Private Label OTC business to include all key retail chains as customers
- Continued to build market share for key products in a challenging competitive environment
- Renegotiated and renewed key supply agreement for continued supply of softgel products
2018
- Develop and launch a pipeline of complementary high barrier to entry generic products from in-house pipeline
- Internalize partnered Rx and OTC products
- Litigate & successfully settle Para IV challenges
2017
- Investment in CoreRx, a Florida based CDMO
- Solidified relationships with key customers
- Started a number of key R&D programs for high barrier generic products
- Repaid acquisition related Term Loan
2016
- Integrated acquired portfolio into Bionpharma's commercial infrastructure
- 10 filings, including 5 Paragraph Ivs
- Built market share of acquired products
2015
- Transformative leveraged portfolio buy-out
- Completed highly challenging transaction on accelerated timeline with limited diligence access
- Portfolio in state of flux upon acquisition
2014
- Bionpharma founded